GET DAILY SIGNALSWhy Is 10x Genomics (TXG) Stock Down -7.36% Today?
Key Takeaways
- Shares of TXG fell 7.36% in intraday trading to $70.03, down from the prior session's close of $75.59.
- No single catalyst emerged; the decline reflects profit-taking and valuation anxiety after a roughly 480% one-year rally.
- Secondary drivers include a technical breakdown below the 50-day moving average and continued insider selling.
- Sector context: the move coincides with broader softness across the life sciences tools and services group.
- What traders are watching next: the company's third-quarter earnings report, scheduled for November 5, 2026.
- For more detail on this ticker, explore Price Targets, Earnings, and Forecast pages.
- To see how AI-driven strategies are positioning across the market, explore Trending AI Robots.
Opening Summary
10x Genomics, Inc. (TXG), a Pleasanton, California-based life sciences technology company that develops single-cell and spatial biology instruments, consumables, and software, saw its shares slide 7.36% on Thursday, falling $5.56 to $70.03 from a prior close of $75.59. The selloff erased a substantial portion of Wednesday's 5.78% gain and extended a choppy pullback from the stock's 52-week high of $102.81 reached in early October. Markets attributed the decline less to any single piece of company news and more to profit-taking, stretched valuation, and a loss of short-term technical momentum.
A Pullback After an Extraordinary Rally
The most important context for Thursday's decline is the scale of the advance that preceded it. TXG has been one of the standout momentum stories of 2026, climbing roughly 480% over the past year and more than 360% year-to-date. The rally was powered by enthusiasm over the company's Atera spatial biology platform, which management has described as a "cornerstone" product with exceptionally strong early order flow, along with an AI pathology partnership, a favorable patent ruling against Qiagen's Parse Biosciences unit, and a wave of analyst price-target increases.
After that kind of run, the stock carries a valuation that is difficult to square with its fundamentals. TXG remains unprofitable on a GAAP basis, with trailing-twelve-month revenue of roughly $617 million and negative operating margins, yet it trades at a price-to-sales multiple well into the mid-teens. Some valuation models place the shares substantially above estimated intrinsic value, which has made the stock increasingly vulnerable to bouts of selling whenever bullish momentum stalls. Thursday's move is consistent with investors locking in gains and reassessing risk rather than reacting to a specific negative headline.
Technical Breakdown and Sector Pressure
The decline also has a clear technical component. After peaking in the $97-to-$102 range in early October, TXG has traced a series of lower highs, and Thursday's slide carried the shares below their 50-day moving average, a level that had acted as support during the rally. Momentum indicators that were deeply overbought in late September have rolled over sharply, signaling weakening near-term buying interest and encouraging momentum-oriented traders to step aside.
The move was reinforced by a softer tone across the life sciences tools and services sector, where high-multiple, high-beta names have come under pressure as investors rotate away from crowded growth trades. Persistent insider selling — company executives and directors have sold tens of millions of dollars' worth of shares in recent months, largely tied to equity vesting — has added a further layer of overhang to the stock's already volatile trading.
Market Context and Trading Activity
Trading in TXG has been unusually heavy and volatile throughout October, with several sessions posting multi-million-share volume well above the stock's historical average and daily swings of 5% or more. The stock's elevated beta reflects its status as a speculative, momentum-driven holding, and it has repeatedly diverged from broader equity indices, moving more violently in both directions than the wider market. Thursday's drop came without a matching decline in the major averages, underscoring that this was a stock-specific de-risking event rather than a broad risk-off session.
What Comes Next for TXG
The next major catalyst for TXG is its third-quarter 2026 earnings report, scheduled for November 5. Investors will be focused on the pace of Atera instrument placements and revenue, whether consumables growth remains resilient, and any update to full-year guidance. Risks include the possibility that customers delay purchases of existing spatial products as they await the Atera ramp, continued pressure on revenue growth, and a valuation that leaves little margin for error if execution disappoints. On the other hand, sustained demand for Atera, AI-driven tailwinds for biological data generation, and a broadly constructive analyst consensus could provide support if near-term momentum stabilizes. For now, the stock's path is likely to remain volatile in both directions ahead of the print.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of AI-powered trading bots that have demonstrated strength under current market conditions. Tickeron offers hundreds of bots covering thousands of tickers, each differing by strategy, timeframe, performance metrics, and traded symbols, but only the strongest performers are featured in this section. Traders interested in systematic approaches may find it useful to explore how these strategies are navigating today's volatile environment.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
TXG in upward trend: price rose above 50-day moving average on October 21, 2026
TXG moved above its 50-day moving average on October 21, 2026 date and that indicates a change from a downward trend to an upward trend. In 28 of 32 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 88%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 9 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +8.16% 3-day Advance, the price is estimated to grow further. Considering data from situations where TXG advanced for three days, in 205 of 265 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
The Aroon Indicator entered an Uptrend today. In 199 of 232 cases where TXG Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 86%.
Bearish Trend Analysis
The 10-day RSI Indicator for TXG moved out of overbought territory on October 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 32 similar instances where the indicator moved out of overbought territory. In 25 of the 32 cases, the stock moved lower in the following days. This puts the odds of a move lower at 78%.
The Momentum Indicator moved below the 0 level on October 08, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on TXG as a result. In 68 of 87 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 78%.
The Moving Average Convergence Divergence Histogram (MACD) for TXG turned negative on October 07, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In 36 of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at 77%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TXG declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
TXG broke above its upper Bollinger Band on September 17, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 7 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (11.930) is normal, around the industry mean (2.923). P/E Ratio (-128.119) is within average values for comparable stocks, (2.388). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.052). Dividend Yield (0.000) settles around the average of (0.009) among similar stocks. P/S Ratio (15.038) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. TXG’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 93 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 95 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TXG’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a life science technology company, which engages in building products to interrogate, understand and master biology
Industry MedicalNursingServices